On the subject of clawback mentioned, inter alia, the Minister of Health Adonis Georgiadisin the context of the 10th Delphi Economic Forumperformed from April 9 to 12.
“When I set up the clawback I was criticized by the universe. But all those who criticized me and then became a government did not touch anything from the clawback. But the clawback was a barbaric meter, agarba made in crisis conditions. Now we need to make measures that will not exclude innovation. We need to take measures that will be flexible and attract innovation, now that it is not an emergency, “said Health Minister Adonis Georgiadis.
Speaking about the data and their exploitation, he said that “Greece will have a huge amount of data by the end of the year. The government’s political will is to make secondary data to be as free as possible. We will go to the maximum that is allowed. ”
Referring to the Memorandum of Understanding between the Ministry of Health and the Pharmaceutical Industry, he noted: “In the final version I will propose throughout the industry this year, I want to be honest in which term cannot be entered. Is the commitment to the height of the clawback. The reason is that the commitment to the state accounting means unknown pharmaceutical expense. It cannot be written in the medium term, because the European institutions will come afterwards and put into the unknown one, go to the extreme scenario and fall out the whole state. “
“We have the budgetary restrictions on the one hand, on the other, an industry that has suffered. The large multinationals have shown a responsibility in the country and have not withdrawn medicines. They honor them because the weak drugs were not deprived when the country had no pay, “he added.
OR Lambrina Barbetakispresident of the Pharma Innovation Forum Greece, Managing Director and Chairman of the Board of Directors of AbbVie Pharmaceutical Greece, Cyprus, Malta, noted: “We do not want a misery thought, but we want a thought. Where are we? We expect that this year our ideas for a framework that promotes innovation will become a practice. It would not be moral on our part to invest. Priority must be given where there are no therapeutic solutions and there is a restriction where they exist. ” She added: “Innovation is based not only on having a significant number of research, but what they find to reach patients. Innovation exists for patients. Innovation that does not reach the patient is not innovation. ”
Concerning public pharmaceutical expenditure, the president and chief executive of Astrazeneca in Greece and Cyprus, was concerned about the “financial gap”. Elena Chouliarastressing: “We are far below southern European countries. The financial gap has exceeded 1 billion to say that we are at the same level as countries like us. There will be difficulties of accessing innovation for Greek patients. And this is important. Pharmaceutical innovation has contributed much to increased life expectancy by 30 years. For our part, we would like some specific commitments from the state mainly to the amount of returns. Obviously we want more predictability and increased funding. ”
The President of Novartis Hellas SA For Greece, Cyprus and Malta, Konstantinos Papagiannishe noted that “I don’t think anyone will leave Delphi and he doesn’t hear about data. We are talking about each panel. And the political leadership sounds like the secondary use, the utilization and analysis that will benefit both the patient and the health professional. “
For its part, the Non -Executive President of EOPYY and Chairman of the Ministry of Health’s Medicines Honor Prices, Basilica-Constantine GogozotouHe said: “We want patients to reach the right medicine at the right time, at the right price. There are many small steps and soon the improvement will be huge. I, as a negotiating committee, want to have the comparative elements of new innovative drugs in relation to the new ones for this condition. They usually present elements of clinical trials compared to earlier treatments, and not with each other, making it difficult to distinguish this innovative treatment that it really excels. Transportant, I would like to access its efficacy data that will confirm the clinical superiority of this treatment. This is for the barbaric clawback
THE George KapetanakisPresident of the Hellenic Cancer Federation of Cancer – ELLOK, noted: “We are very lucky because we have the best team that the Ministry of Health could have. Significant steps have been taken. It came back, we went through difficult years. What I need to say is that although we seem to be on average and access is satisfactory, access raises concerns.
We have not been able to ensure that tomorrow we may have the same access. We have to go to new deals, a new deal. And because the parties involved have different approaches, it must be the decision of the state to promote it. We need to have a program that foreign companies will want to bring medicines to our country.
I am determined to establish innovation fund for innovative treatments and medicines in my term of office
His commitment to proceed with his term as Minister of Health in the implementation of the “Innovation Fund”, as is well known, the funding channel for new innovative treatments and medicines, was expressed by Health Minister Adonis Georgiadis, in the context of the 10th Economist.
More specifically, the Minister of Health referred to the series of initiatives taken by the government, leading to the 1.6 billion -euro investment mobilization in the health sector, while speaking specifically about the innovation or transitional compensation fund, whose aim is to provide a three -year predictability to the markets. He emphasized, however, with regard to the funding of both new resources and redistribution of resources saved by other sectors, a consultation with the Ministry of National Economy and Finance would be required, considering that resources will be required about 100 million per year.
He also emphasized the need for a clear framework with safety valves regarding the drug as he stressed that “the bad past of the country is forcing us to have more controls”. Referring to the US competition in the field of drug, he noted that funding there attracts innovation, resulting in Europe importing 75% of the drugs consumed in the Old Epirus.
Then the Director General of the Foundation for Economic & Industrial Research (IOBE), Professor of the Athens University of Economics and Business, Nikos Vettas He said that “health is not cheap, it needs specialized people, research and growth that costs a lot”, however, stressing that health will be the center of the economy in the coming decades. As he pointed out, innovation is largely attracted to the different US pricing policy by raising questions about autonomy in this field for Europe. In addition, he stressed that state budgets are pending a balancing of the objectives related to generic medicines, while underlining the need to utilize more sources of information that can save resources and change the nature of the health sector. Finally, he emphasized that the national health system was traditionally medical centered, stressing that it should gradually focus on the patient and information.
According to Sanofi’s General Manager of Greece, Hungary and Ukraine, Anthony Aouadpharmaceutical innovation should be a priority for every state if we want a healthy society. In this context, he said that the value of innovation should be recognized and there should be more moves to promote relevant initiatives. As he pointed out, we must reach the European average of drug spending, a sector in which southern Europe is lagging behind. “We have to see it not as an exit, but as an investment,” he noted, stressing that budget redistribution and incentives for clinical trials and research and development.
As the President of the Association of Pharmaceutical Enterprises of Greece (SFEE) noted, Olympios Papadimitriou“Personally, it is difficult for me to imagine duties on medicines in Europe, as this would mean the burden of its state systems, based on public funding,” expressing the hope that there will be no pharmaceutical war as a result of Trump movements, He also emphasized the need to increase the funding for the drug sector which is a tool for a more viable national health system that helps improve patients’ lives and increases life expectancy.
Her personal experience with the National Health System was mentioned by the president of the Union of Patients of Greece, Basilica Rafael Vakouftsisstating that he has been diagnosed with ADDISON’s rare disease for five years. As she said, her life was in danger 13 times due to conventional treatment that did not work while there was an approved drug in Europe that was not available in Greece. As he noted, although it is an incurable disease, it is forced to prove that it is needed every six months that it is needed the treatment it receives and to face the risk of rejection. In this context, he said that only 1 in 5 innovative medicines are available in Greece, underlining the need to hear the voice of minorities facing incurable diseases and the fact that there should be a focus on providing incentives to the pharmaceutical industry for the introduction of medicines. “Investing in innovation is an investment in the future and in society,” he concluded.
Achilles’ shield: The new doctrine of deterrence in the armed forces with 5 -level dome, satellite, “Fremm” frigates and underwater
Crime in Euboea: The house agreement that had until May 8th with the 50 -year -old with the perpetrator did not ask for rent from the 75 -year -old
New angry answer from Tunis: so much money I make, I don’t need ‘Porta Potty’ in Dubai